Genomic Signature of Driver Genes Identified by Target Next‐Generation Sequencing in Chinese Non‐Small Cell Lung Cancer

AbstractBackground.Non‐small cell lung cancer (NSCLC) is one of the most common human malignancies and the leading cause of cancer‐related death. Over the past few decades, genomic alterations of cancer driver genes have been identified in NSCLC, and molecular testing and targeted therapies have become standard care for lung cancer patients. Here we studied the unique genomic profile of driver genes in Chinese patients with NSCLC by next‐generation sequencing (NGS) assay.Materials and Methods.A total of 1,200 Chinese patients with NSCLC were enrolled in this study. The median age was 60 years (range: 26–89), and 83% cases were adenocarcinoma. NGS‐based genomic profiling of major lung cancer‐related genes was performed on formalin‐fixed paraffin‐embedded tumor samples and matched blood.Results.Approximately 73.9% of patients with NSCLC harbored at least one actionable alteration recommended by the National Comprehensive Cancer Network guideline, including epidermal growth factor receptor (EGFR), ALK, ERBB2, MET, BRAF, RET, and ROS1. Twenty‐seven patients (2.2%) harbored inherited germline mutations of cancer susceptibility genes. The frequencies of EGFR genomic alterations (both mutations and amplification) and ALK rearrangement were identified as 50.1% and 7.8% in Chinese NSCLC populations, respectively, and significantly higher than the Western population. Fifty‐six distinct uncommon EGFR mutations other than L858R, exon19del, exon20ins, or T79...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Cancer Diagnostics and Molecular Pathology Source Type: research

Related Links:

In conclusion, the present study provides further understanding of the pathogenesis of LUSC, and reveals CCNB1, CEP55, FOXM1, MKI67 and TYMS as potential biomarkers or therapeutic targets. PMID: 31788059 [PubMed]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Venugopal N, Yeh J, Kodeboyina SK, Lee TJ, Sharma S, Patel N, Sharma A Abstract The discovery of lung carcinoma subtype-specific gene expression changes has the potential to elucidate the molecular differences and provide personalized therapeutic targets for these pathologies. The aim of the present study was to characterize the genetic profiles of the early stages (IA/IB) of two non-small cell lung cancer subtypes, adenocarcinoma (AD) and squamous cell carcinoma (SC). RNA-Seq gene expression data from The Cancer Genome Atlas was analyzed to compare the gene expression differences between AD and SC. The ge...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Zhang H, Luo Y, Xu W, Li K, Liao C Abstract The aberrant expression of long non-coding RNAs is closely associated with drug resistance in multiple types of cancer. Long intergenic non-coding RNA 00707 (LINC00707) has previously been reported to be an oncogene able to promote lung adenocarcinoma cell proliferation and metastasis. However, its role in the progression of cisplatin (DDP) resistance in non-small-cell lung cancer (NSCLC) requires further elucidation. In the present study, LINC00707 and microRNA (miR)-145 expression levels were measured using reverse transcription-quantitative PCR (RT-qPCR). MTT ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
KRAS mutations are the most commonly described alterations in non-small cell lung cancer (NSCLC) Caucasian population accounting for approximately 25% of cases being more frequent in patients with adenocarcinoma histology and smoking history [1]. Although prevalent, unfortunately, no specific treatment has been successfully developed for these patients [2]. With the advent of next generation sequencing (NGS) we have become aware that KRAS-mutated tumors can be associated with co-occurring alterations in multiple genes and with a higher mutational burden [3,4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsThe uptake of [18F]FAMT on PET imaging was significantly correlated with PD-L1 expression in NSCLC, especially in patients with AC and advanced disease.
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
In conclusion, an immune prognostic model was proposed for LUAD that is capable of independently identifying patients at high risk for poor survival, suggesting a relationship between local immune status and prognosis. PMID: 31779055 [PubMed - as supplied by publisher]
Source: J Cell Mol Med - Category: Molecular Biology Authors: Tags: J Cell Mol Med Source Type: research
There are limited data on the clinical efficiency of afatinib in non ‐small cell lung cancer (NSCLC) patients with uncommon epidermal growth factor receptor (EGFR) mutations. Moreover, the efficacy and safety of afatinib in elderly patients with these mutations has not been established. Here, we describe a case of successful treatment of a patient aged>80  years with lung adenocarcinoma positive for the uncommon EGFR L861Q mutation with low‐dose afatinib. An 83‐year‐old woman presented with cough and dyspnea. A chest computed tomography (CT) scan revealed tumors in the left upper lobe, left pleural effusi...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
AbstractEpidermal growth factor receptor (EGFR) gene is frequently mutated in non-small cell lung cancer (NSCLC), which can be targeted by EGFR tyrosine kinase inhibitors (TKIs). It is hard, however, to monitor the performance of EGFR-TKI therapy dynamically. Therefore, therapeutic indicators are urgently needed. Novel antibody microarray, containing 41,472 antibodies, was used for comprehensive analyzing of serum samples from 9 normal subjects and 9 EGFR mutated lung adenocarcinoma patients at three EGFR-TKI treatment time points, including before treatment (Baseline), partial response (PR) during treatment, and disease p...
Source: Journal of Molecular Medicine - Category: Molecular Biology Source Type: research
Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer death [1]. In Asia, the incidence of lung cancer is increasing and Asia accounts for over half of new lung cancer cases diagnosed worldwide [2]. Our understanding of NSCLC has transformed with the discovery of molecular subtypes and therapeutically targetable oncogenic drivers, most notably epidermal growth factor receptor (EGFR) activating mutations, anaplastic lymphoma kinase (ALK) and ROS1 gene rearrangements [3 –5]. As a result, molecular testing for EGFR, ALK and ROS1 is now recommended for all adenocarcinoma NSCLC patients [6].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
A 47 ‐year‐old female with ALK‐rearranged lung adenocarcinoma developed leptomeningeal metastasis (LM) after progression on first‐line crizotinib. Alectinib 300 mg was commenced and the patient achieved clinical and radiographic improvements. After nine months of alectinib 300 mg, she started t o experience symptomatic LM. Two concurrent non‐EML4‐ALK rearrangements,LOC388942 ‐ALK andLINC00211 ‐ALK, were identified from the CSF but not from the plasma samples. With the primary lung lesions remaining stable, the alectinib dose was increased to 600  mg twice daily which alleviated the clinical sy...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | China Health | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Pathology | Study